ASH Highlights on High-Risk MDS in HMA Era: Oral HMAs, BCL2 Inhibition, Macrophage Checkpoint Inhibition, TP53 Modulators

18 views
March 8, 2021
0 Comments
Login to view comments. Click here to Login
6th Annual Updates from ASH 2020